Steve Boyd has been involved in medical device development and commercialization since 1990. He currently serves as Vice President of Research, Development, and Operations for medical device incubator, TheraNova, LLC, and also serves as COO of Potrero Medical, Inc., both in San Francisco, CA. He has held previous positions at ForSight Labs, Opus Medical/ArthroCare, Volcano Corporation, FoxHollow Technologies, and Heartport, Inc. Steve enjoys early stage ventures and the fast pace associated with startup environments and is an inventor in over 50 issued patents and pending applications. He currently lives in San Francisco with his wife and two daughters.
Chris Daniel is Executive Vice President of Operations and Co-Founder of ApniCure. Chris has more than 20 years of experience developing medical devices, primarily in venture-backed startups. At ApniCure, Chris is responsible for operations, including quality, regulatory, manufacturing, finance, and intellectual property. Prior to ApniCure, he was Vice President of Research and Development at Rubicor Medical, where his team obtained six 510(k) clearances and released four products to market. Chris’s experience also includes R&D positions at Heartport and Stryker Endoscopy. He graduated with a B.S. in mechanical engineering from the University of Virginia and an M.B.A. from the Haas School of Business, University of California, Berkeley.
“In the memory and spirit of Dan Rosenman, I am inspired to help foster innovation and entrepreneurship in the medical device industry in California.”
Brian Donlon received his B.S. and M.S. in biomechanical engineering from Stanford University. His research in the Orthopedic Research Lab there focused on tissue engineering and the response of cells to mechanical stresses. He has been working in the medical device industry for over 20 years, including positions in R&D and Marketing at SST/Heartport and Arterial Vascular Engineering/Medtronic, where he has been developing and launching new products around the world for the past 15 years in the Coronary and Renal Denervation business units. He is currently a Senior Director of Global Marketing at Claret Medical. Brian lives in Santa Rosa, California, with his wife and three children.
Sylvia Erickson is a regulatory affairs consultant and 20-year veteran of the medical device industry. Since 2006, she has served as an independent consultant to startups developing implantable and interventional devices in neurology, cardiology, and orthopedics, providing expertise in regulatory submissions. Sylvia previously held R&D engineering roles at Heartport and Evalve. Sylvia received both her B.S. and M.S. degrees in mechanical engineering from Stanford University. She is an inventor/co-inventor named in more than 20 U.S. patents in the medical device field.
“The SF Bay Area is one of the most exciting places to develop new medical devices—the combination of academic institutions, creative doctors, inventive engineers, and venture and angel backers willing to take risks, has created the perfect place to innovate. Dan Rosenman was one of the most inventive and prolific engineers I had the privilege to work with, and it is an honor to help continue the culture of medical device innovation in his memory at the Rosenman Institute.”
Michi Garrison has over 30 years of experience in the medical device industry. She is named inventor or co-inventor on over 50 US patents and has led teams to develop ground-breaking new products and procedures. Michi is currently VP of R&D at Intervene, a start-up medical device company in the venous disease space. She was most recently co-founder and VP of R&D at Silk Road Medical and has also held executive R&D positions at Heartport and CardioVasc.
JEFFRY J. GRAINGER
“I am inspired to be a Rosenman Fellow in order to help the next generation of medical device entrepreneurs turn their ideas into successful companies, and to help make important new therapies available to doctors and patients.”
Jeffry J. Grainger is a Managing Partner at The Foundry, a leading medical device incubator. Prior to joining The Foundry, Mr. Grainger served as Vice President of Corporate Affairs and General Counsel at Xtent, a developer of drug-eluting stent systems that completed an initial public offering in 2007. Mr. Grainger received a J.D. with honors from the University of Washington School of Law and a B.S. in mechanical engineering from Stanford University. Mr. Grainger is an inventor on more than 30 issued or pending U.S. patents, and was a Kauffman Entrepreneur Fellow with the Ewing Marion Kauffman Foundation from 2009 to 2011.
“Just before Dan’s untimely passing, I had started working with Dan at UCSF to help the pediatric and adult surgery groups turn their product ideas into approved medical devices. His engineering and business skills brought needed critical mass to their invention process. Similarly, the Rosenman Institute and its fellows can be key in helping physician and other inventors with the creation of many valuable medical products that might otherwise languish—ones that can truly help the lives of pediatric and adult patients as well as foster additional inventions by first-time inventors.”
Brian Hakim is a Founder and Partner at ECM Medical, a company that helps U.S. medical device companies obtain investment from and bring their products to China. Brian has more than 20 years of experience in medical device development, marketing, and pipeline strategy, primarily in the cardiovascular, orthopedic, and drug delivery areas. Previously, he has served in marketing roles at Medtronic and Velomedix, and in engineering roles at BioCardia, IsoStent, and Baxter Healthcare. Brian has three issued patents and received an M.S. in mechanical engineering from the University of Minnesota and an M.B.A. from the Kellogg School of Management at Northwestern University.
Dr. Michael Harrison is Professor of Surgery, Pediatrics, and Obstetrics, Gynecology and Reproductive Sciences, Emeritus. He is a cum laude graduate of Yale University, who received his M.D. magna cum laude from Harvard Medical School, before going on to general surgical residency training at the Mass General, and finally pediatric surgery fellowship at the Rikshospitalet in Oslo, Norway and Children’s Hospital of Los Angeles. Acknowledged around the world as the “Father of Fetal Surgery,” Dr. Harrison is internationally renown for his expertise and innovation in pediatric and fetal surgery. He was one of the original founders of the International Fetal Medicine Surgery Society, the founder/director of the UCSF Fetal Treatment Center, and now the Director of the UCSF Pediatric Device Consortium. Dr. Harrison is author of more than 400 hundred peer-reviewed articles and several textbooks including three editions of “The Unborn Patient: The Art and Science of Fetal Therapy”. As a member of various medical and surgical professional societies, he has been recognized by his colleagues for his contributions to the field and honored with a number of prestigious awards, including the American College of Surgeons Jacobson Innovation Award, as well as membership into the Institute of Medicine. Recently Dr. Harrison served as the 2009 President for the American Pediatric Surgical Association. He maintains an active research lab, which is currently focused on medical device innovation, development and commercialization, and he is the recipient of one of only three FDA Pediatric Device Consortia grants awarded this past year under the Federal Recovery Act. Dr. Harrison and his wife Gretchen maintain both a residence in the San Francisco Bay Area, and an olive grove in California’s Mendocino County.
Steve Hetts is an Associate Professor of Radiology at UCSF, Chief of Interventional Neuroradiology at UCSF Mission Bay, Co-Director of the UCSF Hereditary Hemorrhagic Telangiectasia Center of Excellence, and Co-Director of the UCSF Interventional Radiology Research Laboratory. As a clinical interventional neuroradiologist, Dr. Hetts treats patients suffering from stroke, brain aneurysms, vascular malformations, and tumors using image-guided minimally invasive approaches. Dr. Hetts' clinical practice informs his research and entrepreneurial efforts in medical devices. Treating infants with retinoblastoma with selective intraarterial chemotherapy led Dr. Hetts to the concept of removing specific chemotherapeutics from the blood to reduce systemic toxicity. This recently led to a research project in the lab, a patent filing, a startup company (ChemoFilter) aided by CTSI and the Rosenman Institute, NIH STTR and R01 grants, and acquisition of ChemoFilter, Inc. by Penumbra. Dr. Hetts runs a core imaging lab at UCSF that provides independent data analysis for device clinical trials in the neurovascular space and has served as a consultant to several neurovascular device companies. He is an author of over 100 peer-reviewed manuscripts and is the principal investigator of two NIH R01 grants. Steve received his AB in Biology from Harvard College, his MD from Harvard Medical School, his internship in Internal Medicine at Stanford, and his Diagnostic Radiology residency, Diagnostic Neuroradiology fellowship, and Interventional Neuroradiology fellowship from UCSF before joining the UCSF faculty in 2008.
Phil Houle has more than 20 years of product development, operations, and business experience in the medical device industry. He is Co-Founder and CEO of OroScience, Inc. Prior to joining OroScience, he worked as Director of Engineering for Aptus Endosystems and Corazon, Inc. Earlier in his career, Phil held positions in project management and engineering at Heartport and DEKA Research and Development Corporation. He is listed as an inventor on 30 issued or pending U.S. Patent applications, and he holds B.S. degrees in zoology and mechanical engineering from the University of Vermont.
“I was inspired to be a Rosenman Fellow because I knew how much Dan would love to see inventions from “the common man” fostered and developed, and joining the team was also a long-awaited opportunity to get the band of Heartport alumni back together. On top of that, I’ve ridden the start-up roller-coaster for many years, and if I can give guidance that will smooth out the journey of a fellow innovator, that’s great!”
Mr. Johnson is the Managing Partner of Revenue River Partners, and he has served startup and Fortune 500 medical device companies in research, design, clinical, marketing, and sales leadership roles. He earned his M.B.A. from the University of Michigan’s Ross Business School, and he holds a Professional Engineer license. Mr. Johnson has innovated, trialed, and commercialized interventional and surgical products in the following clinical arenas: structural heart, coronary, peripheral, ENT, brain, spine, breast, prostate, lung, liver, and bone. With hard work, good judgment, and a little luck, Mr. Johnson has celebrated two IPOs and three acquisitions, while earning several patents and commercializing dozens of new products worldwide.
“When I had first heard of the passing of Dan Rosenman, I realized how quickly life could be taken and truly wanted to do more. During my time at Heartport, I had the pleasure of working with Dan on several projects and admired his passion for developing novel medical devices along with discussions about FDA regulation. The opportunity to help educate and guide the UCSF community on the latest developments from the FDA and other international regulators is the ideal way of ‘doing more,’ and it is my primary reason for being part of the Rosenman Institute under UCSF. My entire career has been about the delivery of new and novel technologies to improve patient quality of life, and I look forward to working with the UCSF community in honor of Dan.”
Kevin MacDonald is currently a regulatory, clinical, and quality consultant working with small medical device startup companies. Kevin has more than 25 years of experience and a successful track record with achieving regulatory market clearances/approvals in the United States and abroad. Prior to his consulting role, Kevin’s recent experience includes Vice President positions at NeoTract and Concentric Medical. Earlier in his career, Kevin held various RA/CA/QA positions with Fox Hollow Technologies, Heartport, Cordis, Boston Scientific Corporation, and CR Bard. Kevin graduated with a B.S. in biology from Framingham State College.
“Medical device start-up investments have slowed in recent years, but innovation hasn't. As a Rosenman Fellow, I am honored to be able to lend my knowledge and experience to help bring to market new medical device technologies.”
Bill has made a 25-year career bringing new medical technologies to market. He is first-named inventor on the majority of 28 issued and numerous pending patents. Currently, he is the COO and CTO of Channel Medsystems, a 12-person cryosurgery device company which he co-founded. Previously, he led R&D efforts at other Bay Area startups and managed more than 60 development programs while he was the Director of R&D at a product design firm. Bill has developed devices for cardiac surgery, cardiology, gynecology, orthopedic surgery, ophthalmology, cosmetic surgery, and laparoscopic surgery. Bill graduated from the Massachusetts Institute of Technology with a B.S. in mechanical engineering.
Rajan Patel is a medical device executive who partners with healthcare brands to transform their design & development practices. After 30+ years of medical device development across drug delivery, diagnostic systems, surgical devices and digital medicine, Rajan knows what truly drives innovation of smart, connected and patient-centric devices. It’s about collaborating with partners who are dedicated to creating breakthrough therapeutic solutions to unmet patient needs. Rajan has held senior positions across such companies as Minimed, Heartport, Aerogen, M2 Medical, Cirtec Medical and Lunar, leading programs to develop & commercialize medical products. Rajan’s commitment over the past 15+ years has been to organizations dedicated to transforming lives through revolutionary drug delivery and medical device technologies. Rajan has led numerous research & development and manufacturing teams to successful execution and launch of life-impacting devices. Rajan holds a B.S. in Mechanical Engineering from MS University of Baroda and M.S. in Biomedical Engineering from UC Davis/CSUS.
“Successful product development is as much art as it is science. Creating the right product for the right customer and being able to scale an idea to make it commercially successful takes a lot of expertise, which comes through experience. The Rosenman Institute nurtures ideas from concept to launch. Often, innovators and new entrepreneurs need a helping hand to create 'customer delighters,' and often these inventions in healthcare save lives. The joy of being able to help create something new and make it successful drives me to be a Rosenman Fellow. These are the very principles Dan Rosenman lived by, and he brings us all together to make an everlasting impact on society.”
Pinaki Ray is a seasoned inventor and entrepreneur, and he has a successful track record in the fields of phlebotomy, cardiac surgery, cardiology, diabetes management software, cancer diagnosis, and treatment software. Pinaki has both worked in successful startups like Heartport and held senior management positions in companies like Johnson & Johnson and Roche. In 2008, he launched an eCommerce venture in the healthcare supply chain space for ambulatory surgery centers. Pinaki holds 10 granted patents and 46 patent applications worldwide. He holds a Masters in Software Business Management from Carnegie Mellon University and graduate degrees in computer science and mechanical engineering.
Carolina Garcia Rizo
Carolina Garcia Rizo has more than 15 years of experience in business development, driving strategic partnerships and leading and executing business plans as well as commercial sales operations in Biotech, with specific focus on Diagnostics. Currently, at Roche, as Director Business Development, she leads all Roche Molecular Business Development and Alliance Management with external Pharma, focusing on Companion Diagnostics collaborations and heads all business development efforts in Oncology and Genomics. Previously at Cepheid, as Director Worldwide Market Development, she drove the turnaround of underperforming markets and new markets penetration. Carolina’s experience also includes strategic consulting at Monitor Group (Deloitte) and commercialization of science at MIT. She was a Fulbright scholar at UC Berkeley during her PhD in sciences (Atomic physics, graduated with honors). She holds an MBA from MIT.
Jeff Royal is Director of Business Development at Abbott where he conducts licensing and acquisition activities for the medical devices division. Jeff has more than 19 years of experience in the medical device industry focused on licensing & acquisitions, corporate strategy, program management, and research and development. Prior to his role in the BD group, he led product development teams at both Abbott Vascular and Guidant, Vascular Intervention to bring new and innovative medical devices from concept through clinical evaluations, and to market introduction. This included ABSORB™, the first bio-absorbable drug eluting coronary implant. Jeff has several patents and received his B.S. in Mechanical Engineering from Michigan State University, and an M.B.A. from the Wharton School of the University of Pennsylvania.
Minnie Sarwal is an MD with an MRCP, FRCP, DCh from London and a PhD in Molecular Genetics from Cambridge University, UK. She is Professor of Surgery at UCSF with prior appointments at Stanford University as Professor of Pediatrics, Immunology and Surgery and Medical Director of the Pediatric Kidney Transplant Program. She was a Founder/CSO of Organ-I, a Stanford University diagnostic company spin-out, sold to Immucor in 2014, which successfully commercialized the kSORT blood multigene assay for predicting kidney transplant rejection. She is also a Founder/CEO of 2 new UCSF spinouts. PPRA and KIT, which stand to improve diagnostics for kidney disease and is an inventor in over 20 patents. She heads an active translational research lab in organ transplantation at UCSF and serves on the Science Board of the FDA. She is a mentor for the UCSF/Berkeley Masters in Translational Medicine Program, serves on NIH study sections and is Chief Editor of a Nature journal; Frontiers in Nephrology. Minnie’s expertise spans new diagnostics and drug discovery/translation, regulatory and clinical trial design. She enjoys the rapid pace of startup environments, innovating, mentoring, teaching and directing patient care. She lives in Portola Valley with her husband and three children and enjoys tennis, piano, art and spending time with her miniature golden retriever.
As a practicing orthopedist, Dr. Sawyer combines experience in orthopedics, physical therapy, and exercise physiology to provide comprehensive skeletal health care. She is the director of the UCSF Skeletal Health Service, which addresses bone health across the human lifespan and provides a multidisciplinary approach to the prevention and healing of fractures. Dr. Sawyer has dedicated a significant portion of her career to developing innovative and impactful healthcare solutions. She helped establish the UCSF Center for Digital Health Innovation, the Digital Health track at UCSF’s Catalyst Accelerator, and the Cisco/UCSF partnership to develop a comprehensive health interoperability platform. Her other leadership roles include serving as an external advisory board member of the Scripps Translational Sciences Institute, as chair of the international health technology advisory board for Murdoch Children's Research Institute in Melbourne, Australia, and as an associate editor of Nature Digital Medicine. Dr. Sawyer earned her MD at UC Davis, and completed a residency in orthopaedic surgery at Stanford, followed by fellowships in pediatric orthopaedic surgery and sports medicine at Boston Children’s Hospital.
Maureen Shaffer has 30 years of cardiovascular and surgical medical device marketing and strategy experience. Maureen has held Vice President positions at startups AtriCure, Inset Medical (now Medasys), and Prolifiq Software. Prior to that, she worked at innovative medical device companies including Heartport, US Surgical (now Covidien), and Cordis.
Maureen is currently CEO of Mingletoe LLC, a company architecting business strategy for early startup and growth-stage medical technology companies. We dig up, mash up, and create powerful, data-backed presentations and models for novel medical device startup companies. Mingletoe synthesizes the chaos of medical device data−market, clinical and economic (reimbursement) to help you build buy-in from your board and generate investment upfront. For commercialization, we develop economic and market models to drive revenue from C-level hospital customers.
Maureen is a rare combination of medtech startup and market strategy savvy with a long-term love for data and software. Her biomedical engineering degree from Duke University lays the foundation for her creative and strategic thinking.
Lawrence Siegel has three decades of experience in medicine, medical devices, and pharmaceuticals, spanning from early invention through commercialization and including major corporate transactions. Currently, he is Chief Scientific Officer at FlexLite. Previously, he served as Chief Medical Officer at ApniCure, PharmacoFore, and Satiety. He was Chief Technology Officer at Heartport and Associate Professor of Anesthesia at Stanford University, where he headed cardiovascular anesthesiology. He remains clinically active, seeing patients and teaching at the VA Palo Alto Health Care System in affiliation with Stanford University School of Medicine. He earned his B.S. in electrical engineering from the Massachusetts Institute of Technology and his M.D. from the Harvard-MIT Program in Health Sciences and Technology.
“One particularly rewarding experience in my career was being part of the Heartport team that developed a novel system for minimally invasive cardiac surgery. This team included cardiologists, cardiac surgeons, and engineers with experience developing a wide variety of devices. In the Rosenman Institute, I’ve found an opportunity to work with a similarly eclectic and even more experienced team to help identify, nurture, and advance promising ideas that will become therapies with broad clinical impact.”
David Snow has been in the medical device industry for over 25 years. His primary expertise is in cardiovascular devices, but he has also developed products for neurovascular, urological, and gynecological applications. He has served as Vice President of R&D for BioCardia and Foxhollow Technologies, and he has held other technical leadership roles at Xtent, Heartport, and Devices for Vascular Intervention. He is an inventor on over 20 U.S. patents. He earned a B.S. in mechanical engineering from Tufts University and an M.S. in mechanical engineering from Stanford University.
Richard Treadwell is President & CEO of Empirical Spine, makers of the LimiFlex™ Paraspinous Tension Band. From January 2011 to October 2015, Mr. Treadwell held the Vice President, Global Marketing position at Singapore-based Biosensors International, the fourth largest coronary stent manufacturer worldwide. In this role, he oversaw the diversification of the product line including the launch of more than 6 new products, and a growth in published medical research on Biosensors products from a rate of 33 to 124 publications annually. Mr. Treadwell has also performed as an active entrepreneur, founding two medtech companies in the San Francisco Bay Area. From 2007 to 2010 he co-founded and led Aardvark Medical, an innovative startup aiming to revolutionize sinus therapy and diagnostics in the clinic and the home. From 2002 to 2006, he founded and ran General Orthodontic (GO), which established the market for advanced technical training and clinical support for dentists and orthodontists using the Invisalign system. He successfully negotiated GO's acquisition by Align Technology. Previously, Mr. Treadwell held positions at EMBOL-X and Nellcor.